Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 8/20 | 0.46 |
| ▸ | HTR1D | P28221 | 5/20 | 0.44 |
| ▸ | HTR1B | P28222 | 3/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26078593 | 0.87 | TAAR1 (0.48) | TAAR1ADRA1AADRA1DADRA1BADRA2C | |
| SCHEMBL26078617 | 0.86 | TAAR1 (0.47) | TAAR1ADRA1AADRA1DADRA1BADRA2C | |
| SCHEMBL26078587 | 0.85 | HTR1D (0.53) | TAAR1ADRA1AADRA1DADRA1BADRA2C | |
| SCHEMBL26078549 | 0.74 | TAAR1 (0.52) | TAAR1ADRA1AADRA1DADRA1BADRA2C | |
| SCHEMBL954710 | 0.74 | TAAR1 (0.67) | TAAR1ADRA1AADRA1DADRA1BADRA2C | |
| SCHEMBL26078523 | 0.74 | TAAR1 (0.70) | TAAR1ADRA1AADRA1DADRA1BADRA2C | |
| SCHEMBL26078482 | 0.72 | TAAR1 (0.56) | TAAR1ADRA1AADRA1DADRA1BADRA2C | |
| SCHEMBL26078590 | 0.72 | HTR1D (0.50) | TAAR1ADRA1AADRA1DADRA1BADRA2C | |
| SCHEMBL5203304 | 0.72 | TAAR1 (0.60) | TAAR1ADRA1AADRA1DADRA1BADRA2C | |
| SCHEMBL26078384 | 0.71 | HTR1D (0.49) | TAAR1ADRA1AADRA1DADRA1BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRA1A, ADRB1, ADRA1D | TAAR1 26/4885ADRA1A 1/4885ADRA1D 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.